Recombinant Mouse Proprotein convertase subtilisin/kexin type 9 (Pcsk9)

1. The data of the present study demonstrated that the PCSK9 shRNAmediated antiapoptotic effect induced by MCAO in hyperlipidemic mice is associated with ApoER2 downregulation, which may be a potential new therapy for stroke treatment in patients with hyperlipidemia. PMID: 30066942
2. It was concluded that quercetin inhibits oxLDLinduced lipid droplets in RAW264.7 cells by upregulation of ABCAl, ABCG1, LXRalpha and downregulation of PCSK9, p53, p21 and p16. PMID: 29845234
3. PCSK9 overexpression in the aorta may promote acute aortic dissection. PMID: 29197601
4. Genetically determined PCSK9 deficiency might be associated with ectopic fat accumulation. PMID: 28758421
5. The present study aimed to explore the direct toxicity of proprotein convertase subtilisin/kexin type 9 (PCSK9) to atherosclerosis (AS) and its association with apoptotic endothelial cells. PMID: 28656218
6. present anti-PCSK9 vaccine induced long-lasting anti-PCSK9 antibody production and improved lipoprotein profiles. Thus, anti-PCSK9 vaccine could become a new option for the treatment of dyslipidemia as a long-acting therapy in future PMID: 29438441
7. PCSK9 may act as an inflammatory mediator in the pathogenesis of atherosclerosis via TLR4/NF-kappaB signaling pathway. PMID: 28535426
8. PCSK9, by sustaining smooth muscle cell synthetic phenotype, proliferation, and migration, may play a pro-atherogenic role in the arterial wall PMID: 27477186
9. PCSK9 inhibits lipoprotein(a) clearance through the LDLR. PMID: 28750079
10. Use Crispr-Cas system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels. PMID: 28751571
11. Studied the combination model of a single AAV-PCSK9 injection, high-fat diet, and partial carotid ligation which induces robust atherosclerosis in the flow-disturbed carotid artery within 3 weeks in C57 mice, and results suggest this is a quick and convenient model to study atherosclerosis and mechanisms using any knockout or transgenic mice without having to generate double knockouts. PMID: 28504688
12. These observations suggest positive feedback interplay between SMC-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis-a hallmark of atherosclerosis. PMID: 27197615
13. AdipoR activation by agonists regulated PCSK9 expression and inhibits atherosclerosis in apoE(-/-) mice. PMID: 28546220
14. Adeno-associated virus mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with angiotensin II. PMID: 27470509
15. conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR degradation and promoting LDLR-dependent hepatic cholesterol uptake. PMID: 27909053
16. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. PMID: 27284008
17. PCSK9 increases hepatic lipid and lipoprotein production via apoE- and LDLR-dependent mechanisms PMID: 26980204
18. Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome. PMID: 27358438
19. polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9. PMID: 26833058
20. binding of PCSK9 to GRP94 protects LDLR from degradation likely by preventing early binding of PCSK9 to LDLR PMID: 26628375
21. The absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR and VLDLR, which is determined by estradiol levels. PMID: 26323289
22. that ox-LDL receptor-1 and PCSK9 positively influence each other's expression, especially during an inflammatory reaction PMID: 26092101
23. Data show that leptin treatment suppresses proprotein convertase subtilisin/kexin type 9 (PCSK9) in male, but fails to suppress PCSK9 in female. PMID: 26824363
24. The Liver Clock Controls Cholesterol Homeostasis through Trib1 Protein-mediated Regulation of PCSK9/Low Density Lipoprotein Receptor (LDLR) Axis. PMID: 26547624
25. PCSK9(-/-) mice display normal sodium balance and blood pressure regulation despite an increase of cleaved alphaENaC under basal condition PMID: 25621930
26. PCSK9-mediated CD36 degradation may serve to limit fatty acid uptake and triglyceride accumulation in tissues, such as the liver and adipose tissue. PMID: 26494228
27. HNF1alpha, but not HNF1beta, is the primary positive regulator of PCSK9 transcription in mouse liver PMID: 25652089
28. high fructose consumption inversely modulates LDL-C and PCSK9 serum levels in mice without a significant impact on liver LDLR protein levels PMID: 25682035
29. PCSK9-reactive oxygen species interaction may be important in the development of atherosclerosis in arterial channels with low shear stress. PMID: 25490141
30. reduced PCSK9 function is associated with increased pathogen lipid clearance. PMID: 25320235
31. Genome editing with the CRISPR-CRISPR-associated 9 system disrupts the Pcsk9 gene in vivo with high efficiency and reduces blood cholesterol levels in mice. PMID: 24916110
32. MMP-2 overexpression may protect the LDLR from PCSK-9-induced degradation. PMID: 25613181
33. PCSK9 markedly increases intestinal triglyceride-rich apoB production through mechanisms mediated in part by transcriptional effects on apoB. PMID: 25070550
34. data revealed a plausible new role of AnxA2 in the reduction of PCSK9 protein levels via a translational mechanism. PMID: 24808179
35. A vicious cycle in LDLR degradation might be generated by PCSK9 induced by hepatic Idol overexpression via dual mechanisms: sterol regulatory element-binding protein 2/LDLR. PMID: 24675665
36. Pcsk9 inactivation decreases the HDL cholesterol concentration and cholesterol efflux capacity in serum, but does not increase atherosclerotic fatty streak volume. PMID: 23883163
37. Low-density lipoprotein receptor (LDLR) is the main route of elimination of proprotein convertase subtilisin/kexin type 9 (PCSK9) and reciprocal regulation between these 2 proteins controls serum PCSK9 levels, hepatic LDLR expression, and serum LDL level. PMID: 23690465
38. Data indicate that FoxO3 and Sirt6 suppress the PCSK9 gene expression and reduce LDL-cholesterol. PMID: 23974119
39. Studies indicate that PCSK9 knockout (KO) (Pcsk9-/-) mice exhibit higher levels of LDLR protein in the liver and less circulating total cholesterol. PMID: 23775089
40. PCSK9 deficiency caused a decrease in several cholesteryl esters (CE) and short fatty acid chain containing sphingolipid species. PMID: 23623011
41. Transintestinal cholesterol excretion is regulated by PCSK9/ABCB1/statins. PMID: 23559630
42. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. PMID: 23135270
43. AnxA2 acts as an endogenous regulator of PCSK9-induced LDLR degradation PMID: 22848640
44. immunization with human-PCSK9 in mice is able to raise antibodies that cross-react and neutralize circulating mouse-PCSK9 protein thus resulting in increased liver LDL receptor levels and plasma cholesterol uptake PMID: 22611251
45. Results indicate that although PPARgamma activation increased PCSK9 expression, PPARgamma activation induced LDLR and CYP7A1 expression that enhanced LDL cholesterol metabolism. PMID: 22593575
46. propose a new role for PCSK9 that involves shuttling between apoB and low-density lipoprotein receptor PMID: 22580899
47. PCSK9 potentiates neuronal apoptosis via modulation of ApoER2 levels and related anti-apoptotic signaling pathways. PMID: 22481440
48. Increased PCSK9 might be responsible for the reduction in LDLR that results from decreased insulin signaling. The mTORC1 inhibitor rapamycin caused increased expression of PCSK9. PMID: 22426206
49. PCSK9 overexpression is proatherogenic. PMID: 22261195
50. PCSK9 downregulates LDLR levels during brain development and following transient ischemic stroke in adult mice PMID: 21518694

Show More

Hide All

KEGG: mmu:100102

STRING: 10090.ENSMUSP00000055757

UniGene: Mm.133268